TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Ikena Oncology ( (IKNA) ) just unveiled an announcement.
On July 1, 2025, Inmagene Biopharmaceuticals announced the successful dosing of the first patient in its global multicenter Phase 2b dose-finding study of IMG-007 for moderate-to-severe atopic dermatitis. This trial is expected to provide critical data for future Phase 3 trials and potentially position IMG-007 as a differentiated therapeutic candidate, minimizing safety risks and offering convenient dosing for patients.
The most recent analyst rating on (IKNA) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Ikena Oncology stock, see the IKNA Stock Forecast page.
Spark’s Take on IKNA Stock
According to Spark, TipRanks’ AI Analyst, IKNA is a Neutral.
Ikena Oncology’s overall stock score of 41.2 reflects significant challenges in financial performance, including declining revenues and negative cash flow, which weigh heavily on the score. Technical analysis shows lackluster momentum, while the valuation is unattractive due to negative earnings. Improvements in revenue generation and profitability are crucial for a better financial outlook.
To see Spark’s full report on IKNA stock, click here.
More about Ikena Oncology
Ikena Oncology, Inc. is a Delaware-based company involved in the biotechnology sector, focusing on innovative therapeutics for immunological and inflammatory diseases. Its primary product, IMG-007, is a humanized monoclonal antibody targeting OX40, currently in Phase 2 development for moderate-to-severe atopic dermatitis and alopecia areata.
Average Trading Volume: 94,677
Technical Sentiment Signal: Sell
Current Market Cap: $65.63M
For a thorough assessment of IKNA stock, go to TipRanks’ Stock Analysis page.